Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc. (NYSE:MRK) unit's R&D center since 2011.

In 2017-18, Li oversaw China approval of more than 10 products for MSD China, including anti-PD-1 mAb Keytruda pembrolizumab, HCV drug Zepatier grazoprevir/elbasvir, HIV drug Isentress raltegravir and HPV vaccines Gardasil and Gardasil 9...